Browse studies

Find your next paid study

10 recruiting studies matching your filters

Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer

Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate canc…

Metastatic Castration-resistant Prostate CancerMetastatic Castration-Resistant Prostate Cancer PatientsMetastatic Castration-resistant Prostate Cancer, mCRPC+2 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

K36 Therapeutics, Inc.NCT07103018

Phase 1

Pilot Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and PD-1 Blockade, With Targeted Ablation of Resistant Lesions, in Patients With Non-Castrate Recurrent Oligometastatic Prostate Cancer

The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab …

Prostate Cancer PatientsNon-castrate Prostate CancerRecurrent Prostate Cancer+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of Wisconsin, MadisonNCT07090148

Phase 2

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to…

Prostate CancerProstate Cancer Patients Treated by Radiotherapy

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Medical University of South CarolinaNCT07325721

Phase 2

A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy

The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remo…

Prostate Cancer (Adenocarcinoma)Prostate CAProstate Cancers+4 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Cellvax Therapeutics IncNCT06636682

Phase 2

Balancing Radiation Intensification and Quality of Life in Higher-Risk Prostate Cancer (The BALANCE-RT Trial)

The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.

Prostate Cancer PatientsNon-metastatic Prostate CancerHigh Risk Prostate Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07751159

Phase 2

Phase II Trial of In-Situ Autologous Vaccination With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Administered to Prostate Cancer Patients on Active Surveillance

This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participa…

Prostate Cancer Patients on Active Surveillance

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Ashutosh Kumar TewariNCT06343077

Phase 2

177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan

The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prost…

Metastatic Castration-Resistant Prostate CancerProstate Cancer Patients With Bone MetastasisProstate Cancer (CRPC)+2 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Ebrahim S DelpassandNCT06972628

Phase 1

A Phase 1 Open-Label, Multicenter Study of JANX013 Combined With JANX007 in Participants With Metastatic Castration Resistant Prostate Cancer

This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the …

Prostate CancerCastration-Resistant Prostate Cancer (CRPC)Metastatic Prostate Cancer+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Janux TherapeuticsNCT07813637

Phase 2

A Biomarker Study in Men With Localized, Favorable, Intermediate-risk Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, interme…

Prostate Cancer Patients Treated by RadiotherapyProstate Cancer (Adenocarcinoma)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Candel Therapeutics, Inc.NCT07332000

Observational

Expanding Genetic Access and Guided Education for Prostate Cancer Survivors

The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will: Test t…

Prostate Cancer PatientsHereditary CancerGenetic Testing

Estimated

~$10 – $750

Actual pay is set by the research site.

Georgetown UniversityNCT07618520